Form 4: Ionis Pharma EVP Sells Shares Under 10b5-1 Plan

Ionis Pharmaceuticals' EVP of Research, Eric Swayze, sold 15,642 shares of common stock on February 13, 2026, under a pre-arranged 10b5-1 trading plan.

Summary

• Eric Swayze, Executive Vice President of Research at IONIS PHARMACEUTICALS INC (IONS), reported a sale of common stock.
• The transactions occurred on February 13, 2026.
• A total of 9,435 shares were sold at a weighted average price of $81.5592 per share.
• An additional 6,207 shares were sold at a weighted average price of $82.0691 per share.
• The sales were executed pursuant to a Rule 10b5-1 Trading Plan adopted by Mr. Swayze on August 14, 2024.
• Following these transactions, Mr. Swayze directly beneficially owns 32,105 shares of common stock.
• Mr. Swayze also indirectly beneficially owns 318 shares through his son.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event given the pre-arranged 10b5-1 plan, which suggests the sale is not based on new, non-public information.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 Trading Plan, indicating it was not based on new, non-public information.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived negatively by investors as it reduces an executive's direct stake in the company.

Management Comments

• Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 14, 2024.

Industry Context

StockSavvy.ai notes that insider sales, even under 10b5-1 plans, are routinely monitored by investors for insights into management's perception of future stock performance. For biotech companies like Ionis, executive stock transactions can sometimes be interpreted in the context of upcoming clinical trial results or regulatory milestones, though this filing provides no such context.

Stakeholder Impact

• Shareholders may view the reduction in executive ownership with slight caution, though the pre-planned nature of the sale mitigates concerns about immediate negative implications.

Key Dates

Recommendation

The sale by an executive, while notable, was conducted under a pre-arranged 10b5-1 plan, indicating it was not based on new, material non-public information. This mitigates the typical negative sentiment associated with insider selling, suggesting no immediate change in the company's fundamental outlook based solely on this transaction.

Keywords

IONIS PHARMACEUTICALS, IONS, Eric Swayze, insider trading, Form 4, stock sale, 10b5-1 plan, executive compensation